Alzheimer’s Disease: More than 5.5 crore people in the whole world are suffering from Alzheimer’s disease. But it is a matter of concern that at present there is no treatment for this disease, which can definitely claim to be cured. Although there has been some progress in recent times in the efforts to find a cure for Alzheimer’s. There has been assistance in the development of two drugs against a dangerous disease like Alzheimer’s. These medicines cannot eliminate the disease from the root, but they can definitely increase the time of progress of the disease.
Considering the effectiveness of these drugs in most of the clinical trials, the treatment starts only after the onset of symptoms. This means that the damage caused to the body by this disease has already happened. However, it is believed that if the treatment of the patients suffering from this disease is started in advance i.e. even before the symptoms appear, then the physical discomfort and suffering caused by it can be prevented. But there is also a problem here that the clinical symptoms, which doctors see to treat Alzheimer’s patients, appear only after neurodegeneration has occurred.
The disease will be detected 10 years ago!
According to the report of the news agency PTI, the recent study of the Karolinska Institute calls for the use of a different biomarker than the one currently used for the diagnosis of Alzheimer’s. The study found that a biomarker, which can be found in a person’s blood, can detect Alzheimer’s up to 10 years before symptoms begin. It provides a chance to stop the ingress of this disease in the body even before its symptoms appear or emerge.
The study, led by Caroline Graf and Charlotte Johansson, used data from Swedish families with a form of Alzheimer’s disease caused by a genetic mutation. If a parent has ADAD, their children have a 50 percent chance of passing on the mutation.
What is GFAP?
According to the study, other tests like MRI imaging and cognitive test were also done to see the symptoms of the disease. The main point of discovery in this study was that the level of a specific protein, called GFAP, increased before the analysis of other known disease-related blood-based biomarkers in the study. This increase started 10 years before the onset of symptoms of Alzheimer’s disease. Explain that GFAP is a protein that is released by astrocytes of the brain. These are special cells, which take part in the immune system of the brain along with other functions. Research also shows that GFAP levels are higher in people who have preclinical Alzheimer’s disease without any genetic cause.
Check out below Health Tools-
Calculate Your Body Mass Index (BMI)